HK53496A - Antiviral use of compositions comprising efas and interferon - Google Patents

Antiviral use of compositions comprising efas and interferon

Info

Publication number
HK53496A
HK53496A HK53496A HK53496A HK53496A HK 53496 A HK53496 A HK 53496A HK 53496 A HK53496 A HK 53496A HK 53496 A HK53496 A HK 53496A HK 53496 A HK53496 A HK 53496A
Authority
HK
Hong Kong
Prior art keywords
gamma
interferons
acid
linolenic acid
acids
Prior art date
Application number
HK53496A
Other languages
German (de)
English (en)
Inventor
Horrobin Frederick
Original Assignee
Scotia Holdings Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scotia Holdings Plc filed Critical Scotia Holdings Plc
Publication of HK53496A publication Critical patent/HK53496A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Claims (3)

  1. Utilisation d'une composition comprenant un ou plusieurs des acides gamma-linolénique, dihomo-gamma-linolénique ou arachidonique et un ou plusieurs interférons pour la fabrication d'un médicament destiné à l'utilisation pour améliorer les effets antiviraux de l'interféron ou des interférons.
  2. Utilisation selon la revendication 1, dans laquelle le médicament est sous forme de dose unitaire et comprend les interférons alpha-béta-gamma, dans des quantités appropriées pour l'administration de 500.000 à 500 millions d'unités/semaine, de préférence de 2 millions à 50 millions d'unités/semaine, tout particulièrement de 5 millions à 25 millions d'unités/semaine, en dose divisée, quotidienne, ou de 2 à 5 fois par semaine, et comprend des acides gras présents chacun dans des quantités convenant pour l'administration de 1 mg à 100 g/jour, de préférence de 10 mg à 10 g et tout particulièrement de 100 mg à 3 g.
  3. Utilisation selon la revendication 1, dans laquelle le médicament est destiné à l'administration locale et comprend des concentrations d'interféron(s) telles qu'elles sont administrées à raison de 100.000 à 10 millions d'unités/ml et dans laquelle la concentration en acide(s) gras est de 1 mg à 300 mg/ml.
HK53496A 1989-08-10 1996-03-28 Antiviral use of compositions comprising efas and interferon HK53496A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB898918294A GB8918294D0 (en) 1989-08-10 1989-08-10 Pharmaceutical compositions

Publications (1)

Publication Number Publication Date
HK53496A true HK53496A (en) 1996-04-03

Family

ID=10661451

Family Applications (1)

Application Number Title Priority Date Filing Date
HK53496A HK53496A (en) 1989-08-10 1996-03-28 Antiviral use of compositions comprising efas and interferon

Country Status (15)

Country Link
US (1) US5580556A (fr)
EP (2) EP0416743B1 (fr)
AT (1) ATE123948T1 (fr)
AU (1) AU633603B2 (fr)
CA (1) CA2022608A1 (fr)
DE (1) DE69020267T2 (fr)
DK (1) DK0416743T3 (fr)
ES (1) ES2073533T3 (fr)
GB (1) GB8918294D0 (fr)
GR (1) GR3016980T3 (fr)
HK (1) HK53496A (fr)
IE (1) IE67773B1 (fr)
NO (1) NO903509L (fr)
NZ (1) NZ234786A (fr)
ZA (1) ZA906187B (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994392A (en) * 1988-02-26 1999-11-30 Neuromedica, Inc. Antipsychotic prodrugs comprising an antipsychotic agent coupled to an unsaturated fatty acid
GB8920228D0 (en) * 1989-09-07 1989-10-18 Efamol Holdings Fatty acid therapy
US5214062A (en) * 1992-04-08 1993-05-25 Clintec Nutrition Co. Method and composition for treating immune disorders, inflammation and chronic infections
GB9304746D0 (en) * 1993-03-09 1993-04-28 Scotia Holdings Plc Treatment of viral infections
US5919815A (en) * 1996-05-22 1999-07-06 Neuromedica, Inc. Taxane compounds and compositions
US5795909A (en) 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
US6576636B2 (en) 1996-05-22 2003-06-10 Protarga, Inc. Method of treating a liver disorder with fatty acid-antiviral agent conjugates
ES2151277T3 (es) * 1996-05-22 2000-12-16 Protarga Inc Composiciones que comprenden conjugados de acido cis-docosahexaenoico y taxotere.
US6225444B1 (en) 1998-02-10 2001-05-01 Protarga, Inc. Neuroprotective peptides and uses thereof
RU2129011C1 (ru) * 1998-04-09 1999-04-20 Григорян Седа Суреновна Способ интерферониндуцирующей или интерферонактивированной терапии и средство для его осуществления
US7235583B1 (en) 1999-03-09 2007-06-26 Luitpold Pharmaceuticals, Inc., Fatty acid-anticancer conjugates and uses thereof
US6426367B1 (en) * 1999-09-09 2002-07-30 Efa Sciences Llc Methods for selectively occluding blood supplies to neoplasias
RU2222548C2 (ru) * 2000-07-21 2004-01-27 Зао "Ниармедик Плюс" Применение производного целлюлозы и госсипола в качестве радиопротекторного, противоинфекционного и потенциирующего средства, усовершенствованный способ его получения и фармацевтическая композиция на его основе
EP1427407A4 (fr) 2001-03-23 2005-05-11 Luitpold Pharm Inc Conjugues a base d'amines gras et d'agents pharmaceutiques
ES2387562T3 (es) 2001-03-23 2012-09-26 Luitpold Pharmaceuticals, Inc. Conjugados alcohol graso-medicamento
RU2238122C1 (ru) * 2003-01-20 2004-10-20 Ооо "Ниармедик Плюс" Противоинфекционный фармацевтический препарат
CA2436650A1 (fr) 2003-08-06 2005-02-06 Naturia Inc. Compositions d'acides linoleniques conjugues : synthese, purification et utilisations
RU2270708C1 (ru) * 2004-05-26 2006-02-27 Ооо "Ниармедик Плюс" Натриевая соль сополимера карбоксиметилцеллюлозы и госсипола, фармацевтическая композиция и способ профилактики или лечения вирусных заболеваний
US8343753B2 (en) * 2007-11-01 2013-01-01 Wake Forest University School Of Medicine Compositions, methods, and kits for polyunsaturated fatty acids from microalgae
GB0907413D0 (en) 2009-04-29 2009-06-10 Equateq Ltd Novel methods
US8293790B2 (en) 2011-10-19 2012-10-23 Dignity Sciences Limited Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof
US9333242B2 (en) 2012-01-19 2016-05-10 Hybrid Medical, Llc Topical therapeutic formulations
US10471131B2 (en) 2012-01-19 2019-11-12 Hybrid Medical, Llc Topical therapeutic formulations
US9682055B2 (en) 2014-06-04 2017-06-20 Dignity Sciences Limted Pharmaceutical compositions comprising DGLA and use of same
US20210315851A1 (en) 2020-04-03 2021-10-14 Afimmune Limited Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2967049D1 (en) * 1978-04-11 1984-07-19 Efamol Ltd Pharmaceutical and dietary composition comprising gamma-linolenic acids
US4513008A (en) * 1982-07-30 1985-04-23 The Vinoxen Company, Inc. Virucidal compositions and therapy
GB2134782B (en) * 1982-09-22 1987-03-04 Sentrachem Ltd Anti-cancer compositions containing higher fatty acids
GB8319073D0 (en) * 1983-07-14 1983-08-17 Efamol Ltd Fatty acid compositions
GB8507058D0 (en) * 1985-03-19 1985-04-24 Efamol Ltd Pharmaceutical & dietary compositions
US5225441A (en) * 1987-06-18 1993-07-06 Block Drug Company, Inc. Treatment of periodontal disease
US5116871A (en) * 1988-09-13 1992-05-26 Efamol Holdings Plc Fatty acid therapy and compositions for the treatment of myalgic encephalomyelitis

Also Published As

Publication number Publication date
CA2022608A1 (fr) 1991-02-11
AU6017890A (en) 1991-02-14
DE69020267D1 (de) 1995-07-27
GR3016980T3 (en) 1995-11-30
DK0416743T3 (da) 1995-08-14
EP0678299A2 (fr) 1995-10-25
NO903509D0 (no) 1990-08-09
DE69020267T2 (de) 1996-01-25
EP0416743A1 (fr) 1991-03-13
ZA906187B (en) 1991-06-26
EP0416743B1 (fr) 1995-06-21
GB8918294D0 (en) 1989-09-20
NZ234786A (en) 1997-06-24
AU633603B2 (en) 1993-02-04
IE902774A1 (en) 1991-02-27
ES2073533T3 (es) 1995-08-16
EP0678299A3 (fr) 1998-11-04
ATE123948T1 (de) 1995-07-15
NO903509L (no) 1991-02-11
US5580556A (en) 1996-12-03
IE67773B1 (en) 1996-04-17

Similar Documents

Publication Publication Date Title
EP0416743B1 (fr) L'utilisation antivirale des compositions comprenant des EFAs et de l'interféron
EP0364094B1 (fr) Utilisation d'aclides gras pour le traitement de l'encéphalomyélite myalgique
EP0440341B1 (fr) Compositions d'acides gras essentiels et thérapie
EP0222483B1 (fr) Utilisation de l'acide gamma-linolénique et des composés apparentés pour l'obtention d'un médicament pour le traitement de l'endométriose
US4970076A (en) Fatty acid composition
EP0132089B1 (fr) Compositions d'acide gras
EP0524796B1 (fr) Utilisation d'acids gras essentiels pour la fabrication d'un médicament pour le traitement du SIDA
US4965075A (en) Methods of increasing 1-series PGs in the body
IE903221A1 (en) Fatty acid therapy
EP0409559B1 (fr) Utilisation pharmaceutique des acides gras
JPH0399011A (ja) 医薬組成物

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)